BTK and cancer: Another study has revealed that ovarian carcinoma cell proliferation and survival were significantly reduced by BTK inhibitors when tested both in vitro (using cell lines) and ex vivo (using cells newly dissociated from human xenografts and cancer cells originating from patients) [32].